Amondys 45 Injection
NDC 60923-227
Product Information
Amondys 45 (casimersen) is a NDA-approved product labeled by Sarepta Therapeutics, Inc.. This medication is typically used as a antisense oligonucleotide [epc]. It is supplied as a injection for intravenous administration. This product entry covers the primary NDC 60923-227 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 60923-227?
What are the uses of this product?
What are Active Ingredients of this product?
- CASIMERSEN 50 mg/mL - FDA approved for the treatment of Duchenne muscular dystrophy.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CASIMERSEN (UNII: X8UHF7SX0R)
- CASIMERSEN (UNII: X8UHF7SX0R) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- POTASSIUM CHLORIDE (UNII: 660YQ98I10)
- POTASSIUM PHOSPHATE, MONOBASIC (UNII: 4J9FJ0HL51)
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2480100 - casimersen 100 MG in 2 ML Injection
- RxCUI: 2480100 - 2 ML casimersen 50 MG/ML Injection
- RxCUI: 2480100 - casimersen 100 MG per 2 ML Injection
- RxCUI: 2480100 - casimersen 50 MG/ML per 2 ML Injection
- RxCUI: 2480105 - Amondys 45 100 MG in 2 ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.